Sumitomo Pharma (Suzhou) Co., Ltd.
Quick facts
Marketed products
- Arotinolol Hydrochloride · Cardiovascular
Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure. - Metoprolol succinate sustained-release tablet
- Non arotinolol group · Cardiovascular
Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions. - Risperidone tablets · Psychiatry/Neurology
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. - Usual dose treatment of Tandospirone · Psychiatry/Neurology
Tandospirone is a serotonin 1A (5-HT1A) receptor agonist that enhances serotonergic neurotransmission in the central nervous system.
Phase 3 pipeline
- Etoposide-Cisplatin combined chemotherapy · Oncology
Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms. - Lurasidone tablets · Psychiatry
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: